News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,991 Results
Type
Article (13872)
Company Profile (102)
Press Release (253017)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88273)
Career Advice (465)
Deals (15381)
Drug Delivery (67)
Drug Development (36771)
Employer Resources (50)
FDA (6349)
Job Trends (6226)
News (150718)
Policy (14101)
Tag
Academia (442)
Accelerated approval (2)
Adcomms (6)
Allergies (36)
Alliances (23283)
ALS (37)
Alzheimer's disease (394)
Antibody-drug conjugate (ADC) (42)
Approvals (6388)
Artificial intelligence (112)
Autoimmune disease (9)
Automation (4)
Bankruptcy (151)
Best Places to Work (4393)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (41)
Bladder cancer (22)
Brain cancer (16)
Breast cancer (83)
Cancer (654)
Cardiovascular disease (76)
Career advice (409)
Career pathing (12)
CAR-T (22)
Cell therapy (89)
Cervical cancer (4)
Clinical research (31089)
Collaboration (356)
Compensation (162)
Complete response letters (17)
COVID-19 (759)
CRISPR (22)
C-suite (127)
Cystic fibrosis (37)
Data (674)
Denatured (15)
Depression (10)
Diabetes (83)
Diagnostics (1328)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (61)
Drug pricing (66)
Drug shortages (12)
Duchenne muscular dystrophy (37)
Earnings (32311)
Editorial (12)
Employer branding (5)
Employer resources (44)
Events (37809)
Executive appointments (401)
FDA (6788)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (215)
Gene editing (41)
Generative AI (9)
Gene therapy (101)
GLP-1 (350)
Government (1307)
Grass and pollen (3)
Guidances (19)
Healthcare (3583)
Huntington's disease (4)
IgA nephropathy (12)
Immunology and inflammation (37)
Indications (15)
Infectious disease (794)
Inflammatory bowel disease (56)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (48)
Interviews (59)
IPO (5896)
IRA (29)
Job creations (2054)
Job search strategy (373)
Kidney cancer (6)
Labor market (12)
Layoffs (182)
Leadership (4)
Legal (3436)
Liver cancer (20)
Lung cancer (87)
Lymphoma (64)
Machine learning (2)
Management (16)
Manufacturing (164)
MASH (33)
Medical device (1299)
Medtech (1301)
Mergers & acquisitions (9693)
Metabolic disorders (265)
Multiple sclerosis (21)
NASH (14)
Neurodegenerative disease (24)
Neuropsychiatric disorders (8)
Neuroscience (584)
NextGen: Class of 2025 (1588)
Non-profit (613)
Now hiring (8)
Obesity (151)
Opinion (119)
Ovarian cancer (22)
Pain (53)
Pancreatic cancer (15)
Parkinson's disease (47)
Partnered (7)
Patents (121)
Patient recruitment (29)
Peanut (10)
People (29055)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8088)
Phase II (13146)
Phase III (11827)
Pipeline (466)
Policy (72)
Postmarket research (1403)
Preclinical (3241)
Press Release (25)
Prostate cancer (48)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (170)
Real estate (2640)
Recruiting (18)
Regulatory (10197)
Reports (14)
Research institute (568)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (37)
Series A (37)
Series B (13)
Service/supplier (3)
Sickle cell disease (32)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1633)
State (2)
Stomach cancer (4)
Supply chain (32)
Tariffs (31)
The Weekly (30)
Vaccines (156)
Venture capitalists (14)
Weight loss (100)
Women's health (8)
Worklife (4)
Date
Today (57)
Last 7 days (265)
Last 30 days (911)
Last 365 days (11835)
2025 (3910)
2024 (12606)
2023 (14321)
2022 (19641)
2021 (20152)
2020 (19125)
2019 (14980)
2018 (11772)
2017 (13934)
2016 (13174)
2015 (15522)
2014 (12445)
2013 (10619)
2012 (11420)
2011 (11944)
2010 (10903)
Location
Africa (313)
Alabama (14)
Alaska (1)
Arizona (56)
Arkansas (3)
Asia (20222)
Australia (2621)
California (1796)
Canada (936)
China (249)
Colorado (71)
Connecticut (70)
Delaware (61)
Europe (39621)
Florida (352)
Georgia (39)
Idaho (9)
Illinois (202)
India (16)
Indiana (136)
Iowa (1)
Japan (96)
Kansas (58)
Kentucky (12)
Louisiana (1)
Maine (2)
Maryland (265)
Massachusetts (1533)
Michigan (30)
Minnesota (95)
Missouri (23)
Montana (8)
Nebraska (7)
Nevada (8)
New Hampshire (6)
New Jersey (786)
New Mexico (7)
New York (534)
North Carolina (403)
North Dakota (2)
Northern California (743)
Ohio (51)
Oklahoma (4)
Oregon (16)
Pennsylvania (472)
Puerto Rico (8)
Rhode Island (10)
South America (505)
South Carolina (2)
Southern California (749)
Tennessee (34)
Texas (237)
United States (7490)
Utah (34)
Virginia (77)
Washington D.C. (31)
Washington State (124)
Wisconsin (17)
266,991 Results for "obi pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science
April 23, 2025
·
12 min read
Press Releases
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC
May 1, 2025
·
4 min read
Press Releases
OBI Pharma Receives ‘Most Promising ADC Clinical Candidate in Taiwan’ Award
March 12, 2025
·
2 min read
Drug Development
OBI Pharma Announces Phase 1/2 Study Initiation for OBI-992, a TROP2-Targeted Antibody-Drug Conjugate (ADC) for Cancer TherapyClinical trial to evaluate the safety and efficacy of OBI-992 in advanced solid tumors.
OBI Pharma, a clinical-stage oncology company, announced the initiation of a Phase 1/2 clinical trial of OBI-992, an antibody-drug conjugate targeting TROP2, an antigen overexpressed in multiple tumor types.
June 12, 2024
·
3 min read
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platformPoster Presentations to highlight the latest research on OBI-992 (anti-TROP2 ADC) and OBI’s novel GlycOBI ADC platform
OBI Pharma, Inc. announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate.
March 18, 2024
·
6 min read
Press Releases
OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI® Enabling Technologies Outreach in Japan and to Advance Glycan Production
December 23, 2024
·
3 min read
Drug Development
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
OBI Pharma, a clinical stage oncology company, announced that the U.S. Food and Drug Administration has cleared an investigational new drug application for OBI-992, to conduct a Phase 1/2 study of its novel antibody - drug conjugate cancer therapy targeting TROP2.
January 3, 2024
·
3 min read
Drug Development
Biosion’s Partner OBI Pharma Announces FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992 (TROP2 ADC)
The Partner of Biosion Inc., OBI Pharma, announced that the U.S. Food and Drug Administration has cleared an investigational new drug application for OBI-992, to conduct a Phase 1/2 study of its novel antibody drug conjugate cancer therapy targeting TROP2.
January 8, 2024
·
4 min read
Business
OBI Pharma Announces Executive Leadership Management Change – Heidi Wang, Ph.D. Appointed as Chief Executive Officer
Dr. Wang appointed by the OBI Pharma Board of Directors as Chief Executive Officer to lead OBI Pharma with a vision and to bring innovative cancer therapies to patients globally.
June 2, 2023
·
3 min read
OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy
OBI Pharma, Inc. announced preclinical data demonstrating significant synergistic effects of OBI-999 and pembrolizumab in four different cancer models, as well as the potent antitumor effect of a chimeric antigen receptor T-cell immunotherapy targeting Globo H.
April 10, 2023
·
3 min read
1 of 26,700
Next
